Education
About Us
Working with TipRanks
Follow Us
Enzolytics (ENZC)
:ENZC
ENZC Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume3.47M
Average Volume (3M)N/A
Market Cap
$2.76M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,941,644,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ENZC FAQ
What was Enzolytics’s price range in the past 12 months?
Enzolytics lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Enzolytics’s market cap?
Enzolytics’s market cap is $2.76M.
When is Enzolytics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enzolytics’s earnings last quarter?
Currently, no data Available
Is Enzolytics overvalued?
According to Wall Street analysts Enzolytics’s price is currently Overvalued.
Does Enzolytics pay dividends?
Enzolytics does not currently pay dividends.
What is Enzolytics’s EPS estimate?
Enzolytics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enzolytics have?
Enzolytics has 3,941,644,000 shares outstanding.
What happened to Enzolytics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Enzolytics?
Currently, no hedge funds are holding shares in ENZC
Company Description
Enzolytics
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
VivoSim Labs
―
Aptevo Therapeutics
―
Enveric Biosciences
―
Ensysce Biosciences
―
Revelation Biosciences
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---